Reid Huber
InvestorPartner at Third Rock Ventures · Board director at Terremotobio · Board director at Synnovation Therapeutics · Board director at Tango Therapeutics
East Coast
Writes $100K – $5M checks · typically $1.5M
About
Reid Huber is a Partner at Third Rock Ventures, which he joined in 2018, where he works on the formation, development and strategy of the firm's portfolio companies. He brings more than 25 years of operating experience in biotechnology, including as a member of the founding scientific team at Incyte in 2002, where he later served as Executive Vice President and Chief Scientific Officer. Earlier in his career he held roles of increasing responsibility at Dupont Pharmaceuticals and Bristol-Myers Squibb, and he completed postdoctoral training at the National Institutes of Health. His investing interests center on companies combining disease genetics, data science and translational medicine to create new medicines.
Contact· published on Reid's own website
Beyond investing
- Founded
- Was a member of the founding scientific team at Incyte in 2002.
- Education
- Earned a B.S. in Molecular Genetics and Biochemistry from Murray State University. Holds a Ph.D. in Human Molecular Genetics from Washington University School of Medicine in St. Louis.
Mentioned above: the Washington University School of Medicine in St. Louis mafia →
From Reid's own website — common ground for a warm intro.
Board director at Terremotobio
Intro paths
In turn, Reid can intro founders to Terremotobio's investors below.
Terremotobio's investors · 6
Board director at Synnovation Therapeutics
Intro paths
In turn, Reid can intro founders to Synnovation Therapeutics's investors below.
Synnovation Therapeutics's investors · 3
Co-founders at Synnovation Therapeutics
Board director at Tango Therapeutics
Intro paths
In turn, Reid can intro founders to Tango Therapeutics's investors below.
Tango Therapeutics's investors · 4
Co-founders at Tango Therapeutics
Experience
- Third Rock VenturesPartnercurrent2018 — presentBoston, MA
- Rapport TherapeuticsDirectorcurrent2022 — presentBoston, Massachusetts, United States
- Rapport TherapeuticsCEO2022 — 2023Boston, Massachusetts, United States
- Merida BiosciencesChairpersoncurrent2024 — presentCambridge, MA
- Merida BiosciencesCEO2024 — 2025Cambridge, Massachusetts, United States
- Synnovation TherapeuticsDirectorcurrent2023 — presentWilmington, Delaware, United States
- Syremis TherapeuticsDirectorcurrent2025 — presentBoston, Massachusetts, United States
- Terremoto BiosciencesDirectorcurrent2021 — presentSan Francisco Bay Area
- Asher BiotherapeuticsDirectorcurrent2021 — present
- insitroBoard Observercurrent2019 — presentSan Francisco Bay Area
- MOMA TherapeuticsDirectorcurrent2020 — present
- MOMA TherapeuticsCEO2020 — 2021Cambridge
- Eastern New Enlgand Board of the American Cancer SocietyDirectorcurrent2020 — presentBoston, Massachusetts, United States
- Partners HealthCare, Innovation Growth BoardDirectorcurrent2019 — presentCambridge, MA
- Bellicum Pharmaceuticals, Inc.Director2014 — 2024Houston, TX
- Tango TherapeuticsDirector2019 — 2023Cambridge, MA
- The Andrew McDonough B+ FoundationDirector2017 — 2019Wilmington, Delaware
- IncyteExecutive Vice President, Chief Scientific Officer2011 — 2018Wilmington, Delaware
- IncyteExecutive Director, Clinical Development2007 — 2011
- IncyteDirector, Applied Technology2005 — 2007
- IncyteAssociate Director, Applied Technology2002 — 2005
- Dupont PharmaceuticalsPrincipal Research Scientist, Applied Biotechnology1998 — 2002
Skills & more
+6 more
PharmacologyMolecular BiologyBiochemistryBiomarker DiscoveryFDAPharmaceutical IndustryFrom Reid's professional profile.
Colleagues at Third Rock Ventures
Frequently asked questions
- Who is Reid Huber?
- Reid Huber is a Partner at Third Rock Ventures, which he joined in 2018, where he works on the formation, development and strategy of the firm's portfolio companies. He brings more than 25 years of operating experience in biotechnology, including as a member of the founding scientific team at Incyte in 2002, where he later served as Executive Vice President and Chief Scientific Officer. Earlier in his career he held roles of increasing responsibility at Dupont Pharmaceuticals and Bristol-Myers Squibb, and he completed postdoctoral training at the National Institutes of Health. His investing interests center on companies combining disease genetics, data science and translational medicine to create new medicines.
- Where does Reid Huber work?
- Reid Huber is Partner at Third Rock Ventures and Board director at Terremotobio and Board director at Synnovation Therapeutics and Board director at Tango Therapeutics.
- What check size does Reid Huber write?
- Reid Huber typically writes checks of $100K – $5M.
- Where did Reid Huber go to school?
- Reid Huber studied at Washington University School of Medicine in St. Louis (PhD, Molecular Genetics/Biochemistry); Murray State University (BS, Molecular Genetics/Biochemistry).
Founder mafias
Third Rock Ventures mafia16
Also came through, then founded or led a company.
+ 9 more
Washington University School of Medicine in St. Louis mafia6
Also came through, then founded or led a company.
Insitro mafia2
Also came through, then founded or led a company.
Merida Biosciences mafia2
Also came through, then founded or led a company.
MOMA Therapeutics mafia2
Also came through, then founded or led a company.
Same school
Also attended Washington University School of Medicine in St. Louis12
+ 6 more
